Skip to content

Vaxcyte, Inc. PCVX Debt-to-assets

Debt-to-assets at other companies

Pfizer logo
PfizerPFE
0.3×0.0×
Merck & Co. logo
Merck & Co.MRK
0.4×+0.1×
Moderna logo
ModernaMRNA
0.1×+0.1×
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
0.0×
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
0.7×-0.4×
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
0.1×0.0×

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$7.43B+72.0%
Enterprise value$7.28B+78.6%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Calculated from Vaxcyte, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vaxcyte, Inc.'s debt-to-assets?
Vaxcyte, Inc. (PCVX) reported debt-to-assets of 0× in Q1 2026.
How has Vaxcyte, Inc.'s debt-to-assets changed year-over-year?
Vaxcyte, Inc.'s debt-to-assets increased by 34.5% year-over-year, from 0× to 0×.
What is the long-term trend for Vaxcyte, Inc.'s debt-to-assets?
Over 5 years (2020 to 2025), Vaxcyte, Inc.'s debt-to-assets has grown at a 76.3% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.